Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Study the efficacy and safety of combining Telitacicept with low-dose corticosteroids in the treatment of IgA nephropathy (IgAN) with crescent formation.
Selecting 72 patients diagnosed with IgAN accompanied by crescent formation through renal biopsy from June 2022 to February 2025 at our hospital as the research subjects, they were divided into a control group (n = 29) and a combination group (n = 43) according to the treatment method. The control group received conventional dose of corticosteroids, while the combination group received Telitacicept combined with low-dose corticosteroids. Clinical efficacy, changes in related indicators before and after treatment (24-hour urinary protein quantification, urinary red blood cell count, serum creatinine, urea nitrogen, serum albumin), and incidence of adverse reactions (acne, moon face, skin striae and ecchymosis, gastrointestinal reactions, infections, liver damage) were compared between the two groups.
The total effective rate after treatment in the combined group (91.3%) was higher than that in the control group (72.6%), with a statistically significant difference (P<0.05). Six months after treatment, the levels of 24-hour urinary protein quantification [(0.66±0.45)g vs. (1.31±0.52)g], urinary red blood cell count [(42.13±22.36) cells/μL vs. (72.16±55.31) cells/μL], serum creatinine [(69.89±19.32)μmol/L vs. (89.31±18.35)μmol/L], urea nitrogen [(4.99±1.61)mmol/L vs. (6.90±1.82)mmol/L] were all lower in the combined group compared to the control group, and the level of serum albumin [(41.22±1.98)g/L vs. (39.69±2.91)g/L] was higher in the combined group, with all differences being statistically significant (P<0.05). The incidence of adverse reactions in the combined group was 42.1%, while it was 37.3% in the control group. Among them, the infection rate in the combined group was slightly higher than that in the control group, but there was no statistically significant difference between the groups (P>0.05).
The combination of Telitacicept with low-dose corticosteroids is significantly effective in treating IgAN with crescent formation, can effectively improve renal function and reduce proteinuria, and has fewer adverse reactions and high safety.
